Antibody Discovery News and Research

RSS

Antibody discovery could explain mysteries about COVID-19 and long COVID

UVA Health researchers have discovered a potential explanation for some of the most perplexing mysteries of COVID-19 and long COVID.

28 Mar 2024

Rapid Novor and MAbSilico partner for world's first AI-guided epitope mapping service for antibodies

Rapid Novor and MAbSilico partner to provide the world's first comprehensive AI-guided epitope mapping service. This service combines hydrogen-deuterium exchange mass spectrometry (HDX-MS) with advanced artificial intelligence (AI)-driven computational modeling.

From Rapid Novor Inc 18 Mar 2024

New study reveals flaws in AI tools used for SARS-CoV-2 antibody discovery

A discovery program for SARS-CoV-2-nABs potentially targeting its resistant strains.

19 Jan 2024

Bridging ideas to IND: Nona Biosciences' year of impact in biotechnology

Amidst a backdrop of industry-wide hurdles like inflation, talent scarcities, and stringent regulatory landscapes, Nona Biosciences is showing great promise as an emerging global leader in biotechnology.

From Nona BioSciences 19 Dec 2023

How next-gen sequencing is changing antibody drug discovery

New study outlines how next-generation sequencing (NGS) and machine-learning methods can revolutionize antibody discovery, particularly against SARS-CoV-2. The research demonstrates that NGS provides greater epitopic and paratopic diversity, enabling more effective identification and prioritization of therapeutic antibodies.

31 Oct 2023

New Sartorius Digital Handbook brings the power of advanced flow cytometry to every scientist

Sartorius, an industry-leading innovator of advanced instruments for cell analysis has released its first Advanced Flow Cytometry Handbook as a comprehensive digital guide to assays and workflows on the iQue® Advanced High Throughput Flow Cytometry Platform.

From Sartorius 26 Oct 2023

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Antiverse Ltd (Antiverse) and GlobalBio, Inc. (GlobalBio) today announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy.

From Antiverse 16 Oct 2023

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

From LabGenius 19 Sep 2023

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.

From Rapid Novor Inc 23 Aug 2023

A hybrid approach to re-engineer a SARS-CoV-1 neutralizing antibody against SARS-CoV-2

A hybrid approach involving a combination of conventional discovery and antibody repurposing to combat COVID-19.

21 Aug 2023

Unleashing the Power of Microfluidic Picodroplets

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Richard Hammond, Chief Technical Officer at Sphere Fluidics, about Sphere Fluidic's microfluidic picodroplet technology and more.

From Sphere Fluidics 21 Aug 2023

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA.

From Sphere Fluidics 6 Jul 2023

Breakthrough: Sequencing functional antibody proteins directly from human blood

Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its REpAb® antibody discovery platform was used to successfully sequence a complex mixture of functional antibodies directly from the serum of a human patient after receiving a COVID-19 vaccine.

6 Jun 2023

The potential clinical benefit of the Multabody platform as a therapeutic for SARS-CoV-2

The potential clinical benefit of the Multabody platform as a therapeutic for SARS-CoV-2.

26 May 2023

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities.

From Bruker Cellular Analysis 16 May 2023

LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark

Through a recent platform demonstration project, LabGenius’ machine learning-driven lead optimisation capability delivered dozens of novel T-cell engagers with best-in-class killing selectivity.

From LabGenius 16 May 2023

Advancing the development of vaccines through recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO at Sino Biological, about current developments in the field of vaccine development through recombinant techniques.

From Sino Biological Inc. 4 May 2023

Research uncovers antibodies that are still effective against new variants of SARS-CoV-2

An anonymous San Diego resident has become a fascinating example of how the human immune system fights SARS-CoV-2.

26 Apr 2023

Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform

Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.

From Antiverse 1 Mar 2023

Researchers develop AI-based strategy for discovering high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

30 Jan 2023